Prostate cancer detection: The value of performing an mri before a biopsy

T. Shimizu, Akihiro Nishie, T. Ro, T. Tajima, A. Yamaguchi, S. Kono, Hiroshi Honda

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: In recent years, prostate-specific antigen (PSA) screening has been widely performed. As a result, patients who need to undergo a complete physical examination for an elevated PSA level have been rapidly increasing. Magnetic resonance imaging (MRI) examination has previously been reported to be effective for the detection of prostate cancer. Purpose: To evaluate the detectability of prostate cancer by performing MRI before biopsy, and to evaluate the relationship between detectability with MRI and cancer location, Gleason score (GS), and tumor size. Material and Methods: MRI was performed at 1.5 Tesla in 122 consecutive patients before biopsy. The detectability of prostate cancer, including sensitivity and positive predictive value (PPV) of transrectal ultrasonography (TRUS), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) (b=2000 s/mm), apparent diffusion coefficient (ADC) map, and biopsy, was calculated using whole-mount section histopathology as a gold standard. In addition, the relationship between the detectability on each MRI sequence and factors such as cancer location (peripheral zone vs. transition zone), GS 510, short-axis diameter (≤4 mm, 59 mm, ≥10 mm), and long-axis diameter (≤9 mm, 1019 mm, ≥20 mm) were also evaluated. Results: The sensitivities of TRUS, T2WI, DWI, ADC map, and biopsy were 26.9%, 41.2%, 56.7%, 57.7%, and 75.1%, respectively, and the PPVs of those modalities were 73.0%, 83.0%, 86.4%, 87.2%, and 91.5%, respectively. There was no correlation between the sensitivity of each MRI sequence and cancer location. The sensitivity of each MRI sequence increased as GS and short- and long-axis diameters of cancer lesions increased. Conclusion: MRI before a biopsy has a high detectability of prostate cancer, particularly with tumor size of more than 5 mm in short-axis diameter or 10 mm in long-axis diameter.

Original languageEnglish
Pages (from-to)1080-1088
Number of pages9
JournalActa Radiologica
Volume50
Issue number9
DOIs
Publication statusPublished - Nov 12 2009

Fingerprint

Prostatic Neoplasms
Magnetic Resonance Imaging
Biopsy
Neoplasm Grading
Neoplasms
Prostate-Specific Antigen
Ultrasonography
Physical Examination

All Science Journal Classification (ASJC) codes

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

Shimizu, T., Nishie, A., Ro, T., Tajima, T., Yamaguchi, A., Kono, S., & Honda, H. (2009). Prostate cancer detection: The value of performing an mri before a biopsy. Acta Radiologica, 50(9), 1080-1088. https://doi.org/10.3109/02841850903216718

Prostate cancer detection : The value of performing an mri before a biopsy. / Shimizu, T.; Nishie, Akihiro; Ro, T.; Tajima, T.; Yamaguchi, A.; Kono, S.; Honda, Hiroshi.

In: Acta Radiologica, Vol. 50, No. 9, 12.11.2009, p. 1080-1088.

Research output: Contribution to journalArticle

Shimizu, T, Nishie, A, Ro, T, Tajima, T, Yamaguchi, A, Kono, S & Honda, H 2009, 'Prostate cancer detection: The value of performing an mri before a biopsy', Acta Radiologica, vol. 50, no. 9, pp. 1080-1088. https://doi.org/10.3109/02841850903216718
Shimizu, T. ; Nishie, Akihiro ; Ro, T. ; Tajima, T. ; Yamaguchi, A. ; Kono, S. ; Honda, Hiroshi. / Prostate cancer detection : The value of performing an mri before a biopsy. In: Acta Radiologica. 2009 ; Vol. 50, No. 9. pp. 1080-1088.
@article{a40a7f28b7164ecabf6724d92be78e77,
title = "Prostate cancer detection: The value of performing an mri before a biopsy",
abstract = "Background: In recent years, prostate-specific antigen (PSA) screening has been widely performed. As a result, patients who need to undergo a complete physical examination for an elevated PSA level have been rapidly increasing. Magnetic resonance imaging (MRI) examination has previously been reported to be effective for the detection of prostate cancer. Purpose: To evaluate the detectability of prostate cancer by performing MRI before biopsy, and to evaluate the relationship between detectability with MRI and cancer location, Gleason score (GS), and tumor size. Material and Methods: MRI was performed at 1.5 Tesla in 122 consecutive patients before biopsy. The detectability of prostate cancer, including sensitivity and positive predictive value (PPV) of transrectal ultrasonography (TRUS), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) (b=2000 s/mm), apparent diffusion coefficient (ADC) map, and biopsy, was calculated using whole-mount section histopathology as a gold standard. In addition, the relationship between the detectability on each MRI sequence and factors such as cancer location (peripheral zone vs. transition zone), GS 510, short-axis diameter (≤4 mm, 59 mm, ≥10 mm), and long-axis diameter (≤9 mm, 1019 mm, ≥20 mm) were also evaluated. Results: The sensitivities of TRUS, T2WI, DWI, ADC map, and biopsy were 26.9{\%}, 41.2{\%}, 56.7{\%}, 57.7{\%}, and 75.1{\%}, respectively, and the PPVs of those modalities were 73.0{\%}, 83.0{\%}, 86.4{\%}, 87.2{\%}, and 91.5{\%}, respectively. There was no correlation between the sensitivity of each MRI sequence and cancer location. The sensitivity of each MRI sequence increased as GS and short- and long-axis diameters of cancer lesions increased. Conclusion: MRI before a biopsy has a high detectability of prostate cancer, particularly with tumor size of more than 5 mm in short-axis diameter or 10 mm in long-axis diameter.",
author = "T. Shimizu and Akihiro Nishie and T. Ro and T. Tajima and A. Yamaguchi and S. Kono and Hiroshi Honda",
year = "2009",
month = "11",
day = "12",
doi = "10.3109/02841850903216718",
language = "English",
volume = "50",
pages = "1080--1088",
journal = "Acta Radiologica",
issn = "0284-1851",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Prostate cancer detection

T2 - The value of performing an mri before a biopsy

AU - Shimizu, T.

AU - Nishie, Akihiro

AU - Ro, T.

AU - Tajima, T.

AU - Yamaguchi, A.

AU - Kono, S.

AU - Honda, Hiroshi

PY - 2009/11/12

Y1 - 2009/11/12

N2 - Background: In recent years, prostate-specific antigen (PSA) screening has been widely performed. As a result, patients who need to undergo a complete physical examination for an elevated PSA level have been rapidly increasing. Magnetic resonance imaging (MRI) examination has previously been reported to be effective for the detection of prostate cancer. Purpose: To evaluate the detectability of prostate cancer by performing MRI before biopsy, and to evaluate the relationship between detectability with MRI and cancer location, Gleason score (GS), and tumor size. Material and Methods: MRI was performed at 1.5 Tesla in 122 consecutive patients before biopsy. The detectability of prostate cancer, including sensitivity and positive predictive value (PPV) of transrectal ultrasonography (TRUS), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) (b=2000 s/mm), apparent diffusion coefficient (ADC) map, and biopsy, was calculated using whole-mount section histopathology as a gold standard. In addition, the relationship between the detectability on each MRI sequence and factors such as cancer location (peripheral zone vs. transition zone), GS 510, short-axis diameter (≤4 mm, 59 mm, ≥10 mm), and long-axis diameter (≤9 mm, 1019 mm, ≥20 mm) were also evaluated. Results: The sensitivities of TRUS, T2WI, DWI, ADC map, and biopsy were 26.9%, 41.2%, 56.7%, 57.7%, and 75.1%, respectively, and the PPVs of those modalities were 73.0%, 83.0%, 86.4%, 87.2%, and 91.5%, respectively. There was no correlation between the sensitivity of each MRI sequence and cancer location. The sensitivity of each MRI sequence increased as GS and short- and long-axis diameters of cancer lesions increased. Conclusion: MRI before a biopsy has a high detectability of prostate cancer, particularly with tumor size of more than 5 mm in short-axis diameter or 10 mm in long-axis diameter.

AB - Background: In recent years, prostate-specific antigen (PSA) screening has been widely performed. As a result, patients who need to undergo a complete physical examination for an elevated PSA level have been rapidly increasing. Magnetic resonance imaging (MRI) examination has previously been reported to be effective for the detection of prostate cancer. Purpose: To evaluate the detectability of prostate cancer by performing MRI before biopsy, and to evaluate the relationship between detectability with MRI and cancer location, Gleason score (GS), and tumor size. Material and Methods: MRI was performed at 1.5 Tesla in 122 consecutive patients before biopsy. The detectability of prostate cancer, including sensitivity and positive predictive value (PPV) of transrectal ultrasonography (TRUS), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) (b=2000 s/mm), apparent diffusion coefficient (ADC) map, and biopsy, was calculated using whole-mount section histopathology as a gold standard. In addition, the relationship between the detectability on each MRI sequence and factors such as cancer location (peripheral zone vs. transition zone), GS 510, short-axis diameter (≤4 mm, 59 mm, ≥10 mm), and long-axis diameter (≤9 mm, 1019 mm, ≥20 mm) were also evaluated. Results: The sensitivities of TRUS, T2WI, DWI, ADC map, and biopsy were 26.9%, 41.2%, 56.7%, 57.7%, and 75.1%, respectively, and the PPVs of those modalities were 73.0%, 83.0%, 86.4%, 87.2%, and 91.5%, respectively. There was no correlation between the sensitivity of each MRI sequence and cancer location. The sensitivity of each MRI sequence increased as GS and short- and long-axis diameters of cancer lesions increased. Conclusion: MRI before a biopsy has a high detectability of prostate cancer, particularly with tumor size of more than 5 mm in short-axis diameter or 10 mm in long-axis diameter.

UR - http://www.scopus.com/inward/record.url?scp=70449098938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449098938&partnerID=8YFLogxK

U2 - 10.3109/02841850903216718

DO - 10.3109/02841850903216718

M3 - Article

C2 - 19863420

AN - SCOPUS:70449098938

VL - 50

SP - 1080

EP - 1088

JO - Acta Radiologica

JF - Acta Radiologica

SN - 0284-1851

IS - 9

ER -